0
     

Report Added
Report already added
Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028

Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028

Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028 Report Highlights:

• Global Orphan Designated Market Opportunity > USD 170 Billion by 2028
• Global & Regional Market Size 2022 Till 2028
• Market Size By Orphan Designated Cancer Type 2022 Till 2028
• Top 50 Orphan Designated Cancer Drug Sales Forecast Till 2028
• Top 50 Drugs Account For > 70% Of Global Orphan Cancer Drug Market
• Top 50 Drugs Pricing, Dosage, Patent Insight
• Orphan Designated Cancer Drug Clinical Trials Insight by Company, Country & Indication
• Insight On More Than 400 Orphan Designated Cancer Drugs in Clinical Trials
• Insight On More Than 200 Orphan Designated Cancer Drugs Commercially Available in Market

Orphan cancer drugs are novel pharmaceuticals which are indicated for the prevention, diagnosis, or treatment of rare cancers. These rare cancers are chronic and life-threatening which requires proper long-term medications. As these diseases are rare, therefore the drug development of these diseases requires considerable amount of investment, thus increasing the overall cost of the drug. However, the passage of orphan drug development act in 1983 has opened avenues for the development of novel orphan drugs which are intended for the management of these cancers. The passage of this act incentivizes the pharmaceutical companies to actively invest in this segment. Till date, more than 700 drugs have been granted orphan designation for the management of orphan designated cancers.

This rapid increase in the designation also appears to have translated into an increase in approvals and commercialization of these drugs. As of now, more than 200 drugs have been commercially available for the management of rare cancers. Several biological drugs such as Herceptin, Rituximab, Blincyto, Kymriah, Opdivo, Keytruda, Yervoy, and others have been granted orphan designations which have shown encouraging response in the market owing to their targeted mechanism of action. The sales of these drugs have been tremendously increasing from past few years, which have encouraged the further research and development activities in this domain.

The global orphan cancer drug market is highly concentrated with several key layers including Mersana Therapeutics, Bristol Myers Squibb, Immunocore, Amgen, Genmab, Roche, Lava Therapeutics, and others. The key players are actively receiving orphan drug designation by the regulatory bodies which are expediting their clinical trials and approval process. For instance in 2022, Mersana Therapeutics has received orphan drug designation from US FDA to XMT-2056 for the management of gastric cancer. XMT-2056 is an investigational STING-agonist antibody drug conjugate (ADC) which is developed using the company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). The company has planned to initiate phase-I trial of XMT-2056 in a range of HER2 expressing tumors, such as breast, gastric and non-small-cell lung cancers, in mid 2022.

In last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to mitigate the obstacles of drug development. For instance, Immunocore entered into clinical trial collaboration and supply agreement with Sanofi. Under the terms of agreement, Sanofi will evaluate it’s precisely PEGylated, engineered version of IL-2, SAR444245, in combination with Kimmtrak, Immunocore’s novel bispecific protein targeting gp100, in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers as part of Sanofi’s ongoing Phase 1/2 study. The novel bispecific protein has been granted orphan drug designation by US FDA.

Despite several benefits associated with orphan cancer drug development, few factors restrain their growth in the market during the forecast period. Factors such as high cost of therapy, low prevalence of disease, difficulty in recruiting patients, lack of awareness among patients, and unavailability of diagnostic test for rare cancer hamper the growth of market. Although several challenges restrict the growth of market, but it is witnessed that the global orphan cancer drug market is continuously growing from past few years.

As per our report findings, the global orphan cancer drug market is expected to surpass US$ 150 Billion by 2028 which is mainly attributed to increase in prevalence of rare cancers associated with high demand for the orphan drugs in its management. The high spending on research and development of orphan cancer drugs, coupled with the presence of several large scale manufacturers are the major factoring driving the growth of market. Apart from this, several pharmaceutical companies like Amgen, Roche, Genetech have developed their assistance programs through which their potentially lower down the out-of pocket cost from the patients.
Table of Contents

1. Research Methodology

2. Introduction To Orphan Drugs

3. Global Orphan Drug Designation Criteria
3.1 US
3.2 Europe
3.3 Asia & Australia

4. Market Exclusivity & Patent Protection for Orphan Drugs

5. Global Orphan Designated Cancer Drug Market
5.1 Current Market Scenario
5.2 Future Market Opportunity

6. Orphan Designated Cancer Drug Market Insight by Region
6.1 US
6.2 Europe
6.3 Japan
6.4 South Korea
6.5 China
6.6 Australia
6.7 UK
6.8 Canada
6.9 Middle East

7. Global Orphan Designated Cancer Drug Market by Indication
7.1 Lymphoma
7.2 Leukemia
7.3 Lung Cancer
7.4 Multiple Myeloma
7.5 Ovarian Cancer
7.6 Gastric Cancer
7.7 Thyroid Cancer
7.8 Liver Cancer
7.9 Pancreatic Cancer
7.10 Melanoma
7.11 Brain Cancer
7.12 Renal Cell Carcinoma

8. Top 50 Orphan Designated Cancer Drugs - Availability, Dosage, Price & Sales Forecats 2028

THIS CHAPTER GIVES COMPREHENISVE CLINICAL & COMMERCIAL INSIGHT ON TOP 50 ORPHAN DESIGNATED CANCER DRUGS. THESE DRUGS ACCOUNT FOR MORE THAN 70% OF TOTAL ORPHAN DESIGNATED CANCER DRUG MARKET. MORE THAN 500 CHARTS & GRAPHS REPRESENTING SALES, PATENT, PRICING, DOSAGE, APPROVAL YEAR INSIGHT ON TOP 50 ORPHNA DESIGNATED CANCER DRUGS.

9. Global Orphan Cancer Drugs Clinical Pipeline Overview
9.1 By Company
9.2 Drug Class
9.3 Indication
9.4 Priority Status
9.5 By Phase

10. Global Orphan Cancer Drugs Clinical Pipeline By Company, Country , Indication & Phase
10.1 Preclinical
10.2 Phase-I
10.3 Phase-I/II
10.4 Phase-II
10.5 Phase-II/III
10.6 Phase-III
10.7 Preregistration
10.8 Registered

11. Marketed Orphan Cancer Drugs Clinical Insight By Company, Country & Indication

12. Competitive Landscape
12.1 AOP Orphan
12.2 Agenus
12.3 Alexion
12.4 Bristol Myers Squibb
12.5 Biogen Idec
12.6 Celgene
12.7 Eli Lilly
12.8 Genethon
12.9 Genzyme Corporation
12.10 Glaxosmithkline
12.11 Merck
12.12 Novartis Pharmaceuticals
12.13 Orphan Europe
12.14 Pfizer
12.15 Prosensa
12.16 Rare Disease Therapeutics
12.17 Roche
12.18 Sanofi
12.19 Shire
12.20 Teva Pharmaceutical

List Of Figures

Figure 5-1: Global – Rare vs. Other Cancer Prevalence (%)
Figure 5-2: Global – Top 10 Orphan Cancer Drug Sales (US$ Billion), 2021
Figure 5-3: Global – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 5-4: Orphan Cancer Drugs – Sales Value by Region (US$ Billion), 2021
Figure 5-5: Orphan Cancer Drugs – Sales Value by Region (%), 2021
Figure 5-6: Global – Sales of Orphan Designated Cancer Drugs (US$ Billion), 2022 – 2028

Figure 6-1: US – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-2: US vs. ROW – Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-3: US vs. ROW – Sales of Orphan Cancer Drugs (%), 2021
Figure 6-4: US – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-5: Europe – Orphan Drug Designation by Indication, 2021
Figure 6-6: Europe – Orphan Drug Designation by Indication (%), 2021
Figure 6-7: Europe – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-8: Europe vs. ROW – Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-9: Europe vs. ROW – Sales of Orphan Cancer Drugs (%), 2021
Figure 6-10: Europe – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-11: Japan – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-12: Japan vs. ROW – Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-13: Japan vs. ROW – Sales of Orphan Cancer Drugs (%), 2021
Figure 6-14: Japan – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-15: South Korea – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-16: South Korea – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-17: China – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-18: China – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-19: Australia – Average Incidences & Deaths of Rare Cancer
Figure 6-20: Australia – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-21: Australia – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-22: UK – Orphan Drug Designation by Indication, 2021
Figure 6-23: UK – Orphan Drug Designation by Indication (%), 2021
Figure 6-24: UK – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-25: UK vs. ROW – Sales of Orphan Cancer Drugs (US$ Billion), 2021
Figure 6-26: UK vs. ROW – Sales of Orphan Cancer Drugs (%), 2021
Figure 6-27: UK – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-28: Canada – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-29: Canada – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028
Figure 6-30: Middle East – Sales of Orphan Cancer Drugs (US$ Billion), 2020 & 2021
Figure 6-31: Middle East – Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028

Figure 7-1: Global – Sales of Orphan Designated Lymphoma Drugs (US$ Billion), 2021 - 2028
Figure 7-2: Global – Sales of Leukemia Designated Orphan Drugs (US$ Billion), 2021 - 2028
Figure 7-3: Global – Sales of Lung Cancer Designated Orphan Drugs (US$ Billion), 2021 - 2028
Figure 7-4: Global – Sales of Multiple Myeloma Designated Orphan Drugs (US$ Billion), 2021 - 2028
Figure 7-5: Global – Sales of Ovarian Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-6: Global – Sales of Gastric Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-7: Global – Sales of Thyroid Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-8: Global – Sales of Liver Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-9: Global – Sales of Pancreatic Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-10: Global – Sales of Melanoma Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-11: Global – Sales of Brain Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028
Figure 7-12: Global – Sales of Renal Cell Carcinoma Designated Orphan Drugs (US$ Million), 2021 - 2028

Figure 8-1: Rituxan – FDA Approval Year by Indication
Figure 8-2: Rituxan – FDA Orphan Designation Year by Indication
Figure 8-3: Rituxan – Price for a Supply of 10 ml & Price Per ml of Injection (US$), June’2022
Figure 8-4: Rituxan – Price for a Supply of 50 ml & Price Per ml for Injection (US$), June’2022
Figure 8-5: Rituxan – Price for a Supply of 100 ml & Price Per ml for Injection (US$), June’2022
Figure 8-6: Rituxan Combination – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June’2022
Figure 8-7: Rituxan Combination – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), June’2022
Figure 8-8: Rituxan – Value by Region (US$/CHF Million), Q1’2022
Figure 8-9: Global - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-10: US - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-11: Europe - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-12: Japan - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-13: ROW - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 8-14: Rituxan - Sales Value by Region (US$/CHF Million), 2021
Figure 8-15: Rituxan - Sales Value by Region (%), 2021
Figure 8-16: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 8-17: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 8-18: Global - Rituxan Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-19: US - Rituxan Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-20: Yervoy – US & Europe Exclusivity Expiration Year
Figure 8-21: Yervoy – FDA Orphan Designation Year by Indication
Figure 8-22: Yervoy - Price for 10ml Supply & Price Per ml of 5mg/ml Intravenous Injection (US$), June’2022
Figure 8-23: Yervoy – Price for 40ml Supply & Price Per ml 5mg/ml Intravenous Injection (US$), June’2022
Figure 8-24: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (Weeks), June’2022
Figure 8-25: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (US$), June’2022
Figure 8-26: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), June’2022
Figure 8-27: Global - Yervoy Sales Value by Region (US$ Million), Q1’2022
Figure 8-28: Global - Yervoy Sales Value by Region (%), Q1’2022
Figure 8-29: Yervoy – Sales Value (US$ Billion), 2016-2021
Figure 8-30: Yervoy – Sales by Region (US$ Million), 2021
Figure 8-31: Yervoy – Sales by Region (US$ Million), 2021
Figure 8-32: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 8-33: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 8-34: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 8-35: Yervoy – Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 8-36: US - Yervoy Quarterly Sales Value (US$ Million), 2019
Figure 8-37: Yervoy – US v/s Rest of World Sales Share (%), 2019
Figure 8-38: Global - Yervoy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-39: US - Yervoy Sales Forecast (US$ Million), 2022 - 2028
Figure 8-40: Opdivo - Patent Expiration Year by Region
Figure 8-41: Opdivo – US FDA Orphan Designation Year by Indication
Figure 8-42: Opdivo - Price for 4ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022
Figure 8-43: Opdivo - Price for 10 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022
Figure 8-44: Opdivo - Price for 12 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022
Figure 8-45: Opdivo - Price for 24 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022
Figure 8-46: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June’2022
Figure 8-47: Global - Opdivo Sales Value by Region (US$ Million), Q1’2022
Figure 8-48: Global - Opdivo Sales Value by Region (%), Q1’2022
Figure 8-49: Global - Opdivo Sales Value (US$ Million), 2016 - 2021
Figure 8-50: US - Opdivo Sales Value (US$ Million), 2016 - 2021
Figure 8-51: Opdivo – Sales by Region (US$ Million), 2021
Figure 8-52: Opdivo – Sales by Region (US$ Million), 2021
Figure 8-53: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 8-54: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 8-55: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 8-56: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 8-57: Global – Opdivo Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-58: US – Opdivo Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-59: Kyprolis – Proteolix Inc’s Patents Issue & Expiration Year
Figure 8-60: Kyprolis – Cydex Pharmaceutical’s Patent Issue & Expiration Year
Figure 8-61: Kyprolis – Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
Figure 8-62: Kyprolis – Price of 10mg, 30mg & 60mg Intraveneous Powder for Injection (US$), June’2022
Figure 8-63: Kyprolis – Initial Dose & Maintainence Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)
Figure 8-64: Kyprolis - Initial Dose & Maintainence Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
Figure 8-65: Kyprolis – Sales by Region (US$ Million), Q1’2022
Figure 8-66: Kyprolis – Sales by Region (US$ Million), Q1’2022
Figure 8-67: Kyprolis – Sales Value (US$ Million), 2018 - 2021
Figure 8-68: Kyprolis – Sales by Region (US$ Million), 2021
Figure 8-69: Kyprolis – Sales by Region (US$ Million), 2021
Figure 8-70: Global - Kyprolis Quarterly Sales Value (US$ Million), 2021
Figure 8-71: US - Kyprolis Quarterly Sales Value (US$ Million), 2021
Figure 8-72: Global - Kyprolis Quarterly Sales Value (US$ Million), 2020
Figure 8-73: US - Kyprolis Quarterly Sales Value (US$ Million), 2020
Figure 8-74: Global – Kyprolis Sales Forecast (US$ Million), 2022 - 2028
Figure 8-75: US - Kyprolis Sales Forecast (US$ Million), 2022 - 2028
Figure 8-76: Revlimid – FDA Approval Year by Indication
Figure 8-77: Revlimid – FDA Approval & Patent Expiration Year
Figure 8-78: Revlimid – FDA Orphan Designation Year by Indication
Figure 8-79: Revlimid – Price for 28 capsules & 100 Capsules of 2.5mg, 5mg & 10mg Capsules (US$), June’2022
Figure 8-80: Revlimid – Price for 21 capsules & 100 Capsules of 15mg, 20mg & 25mg Capsules (US$), June’2022
Figure 8-81: Revlimid – Recommended Daily Dose by Indications (mg)
Figure 8-82: Revlimid – Sales by Region (US$ Million), Q1’2022
Figure 8-83: Revlimid – Sales by Region (US$ Million), Q1’2022
Figure 8-84: Global – Revlimid Sales Value (US$ Million), 2017 - 2021
Figure 8-85: US – Revlimid Sales Value (US$ Million), 2017 - 2021
Figure 8-86: Revlimid – Sales by Region (US$ Million), 2021
Figure 8-87: Revlimid – Sales by Region (US$ Million), 2021
Figure 8-88: Global - Revlimid Quarterly Sales Value (US$ Million), 2021
Figure 8-89: US - Revlimid Quarterly Sales Value (US$ Million), 2021
Figure 8-90: Global - Revlimid Quarterly Sales Value (US$ Million), 2020
Figure 8-91: US - Revlimid Quarterly Sales Value (US$ Million), 2020
Figure 8-92: Global – Revlimid Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-93: US – Revlimid Sales Forecast (US$ Million), 2022 - 2028
Figure 8-94: Velcade – FDA Approval Year by Indication
Figure 8-95: Velcade – Patent Issue & Expiration Year
Figure 8-96: Velcade – US FDA Orphan Designation Year by Indication
Figure 8-97: Bortezomib – Generic Approval By Companies
Figure 8-98: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US$), June’2022
Figure 8-99: Velcade – Minimum & Maximum Cost of Single Treatment Cycle (US$), June’2022
Figure 8-100: Global – Velcade Sales Value (JPY/US$ Billion), 2017 - 2021
Figure 8-101: Global – Velcade Quarterly Sales Value (JPY/US$ Billion), Q1-Q3’2021
Figure 8-102: US – Velcade Sales Value (JPY/US$ Billion), 2018 - 2021
Figure 8-103: Global – Velcade Sales Value by Region (%), 2020
Figure 8-104: Global – Velcade Sales Forecast (US$ Million), 2022 - 2028
Figure 8-105: US – Velcade Sales Forecast (US$ Million), 2021-2026
Figure 8-106: Pomalyst – FDA Approval & Patent Expiration Year
Figure 8-107: Pomalyst – US FDA Orphan Designation Year by Indication
Figure 8-108: Pomalyst – Orphan Designation Year by Region
Figure 8-109: Pomalyst – Price for 21 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), June’2022
Figure 8-110: Pomalyst – Price for 100 Capsules Supply & Price per unit Capsule of Various Dose Regimens (US$), June’2022
Figure 8-111: Pomalyst – Recommended Initial & Reduced Dose (mg/day)
Figure 8-112: Pomalyst – Sales by Region (US$ Million), Q1’2022
Figure 8-113: Pomalyst – Sales by Region (US$ Million), Q1’2022
Figure 8-114: Global - Pomalyst Sales Value (US$ Million), 2017 - 2021
Figure 8-115: Pomalyst – Sales by Region (US$ Million), 2021
Figure 8-116: Pomalyst – Sales by Region (US$ Million), 2021
Figure 8-117: Pomalyst – US v/s Rest of World Sales Value (US$ Million), 2020
Figure 8-118: Pomalyst – US v/s Rest of World Sales Value (%), 2020
Figure 8-119: Global - Pomalyst Quarterly Sales Value (US$ Million), 2021
Figure 8-120: US - Pomalyst Quarterly Sales Value (US$ Million), 2021
Figure 8-121: Global - Pomalyst Quarterly Sales Value (US$ Million), 2020
Figure 8-122: US - Pomalyst Quarterly Sales Value (US$ Million), 2020
Figure 8-123: Global – Pomalyst Sales Forecast (US$ Million), 2022 - 2028
Figure 8-124: US – Pomalyst Sales Forecast (US$ Million), 2022 - 2028
Figure 8-125: Sprycel – FDA Approval Year by Tablet Strength
Figure 8-126: Sprycel – Patent Issue & Expiration Year
Figure 8-127: Sprycel – US FDA Orphan Designation Issue & Exclusivity Expiration Year
Figure 8-128: Sprycel – Price for 60 Tablets & Price per Unit Tablet of 20mg, 50mg and 70mg (US$), June’2022
Figure 8-129: Sprycel – Price for 30 Tablets & Price per Unit Tablet of 80mg, 100mg and 140mg (US$), June’2022
Figure 8-130: Sprycel – Recommended Dose by Indication (mg/day)
Figure 8-131: Sprycel – Recommended Pediatric Dose by Weight (mg/day)
Figure 8-132: Sprycel – Sales by Region (US$ Million), Q1’2022
Figure 8-133: Sprycel – Sales by Region (US$ Million), Q1’2022
Figure 8-134: Global - Sprycel Sales Value (US$ Million), 2018 - 2021
Figure 8-135: US - Sprycel Sales Value (US$ Million), 2018 - 2021
Figure 8-136: Sprycel – Sales by Region (US$ Million), 2021
Figure 8-137: Sprycel – Sales by Region (US$ Million), 2021
Figure 8-138: Sprycel – US v/s Rest of World Sales Value (US$ Million), 2020
Figure 8-139: Sprycel – US v/s Rest of World Sales Value (%), 2020
Figure 8-140: Global - Sprycel Quarterly Sales Value (US$ Million), 2021
Figure 8-141: US - Sprycel Quarterly Sales Value (US$ Million), 2021
Figure 8-142: Global - Sprycel Quarterly Sales Value (US$ Million), 2020
Figure 8-143: Global – Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 8-144: US – Sprycel Sales Forecast (US$ Million), 2022 - 2028
Figure 8-145: Imbruvica – FDA Approval Year by Indication
Figure 8-146: Imbruvica – FDA Orphan Designation Year by Indication
Figure 8-147: Imbruvica – FDA Approval Year by Dosage Form
Figure 8-148: Imbruvica – Approval Year by Region
Figure 8-149: Ibrutinib – Patent & Exclusivity Expiration Year
Figure 8-150: Imbruvica – Price for 90 & 120 Capsule Supplies of 140mg (US$), June’2022
Figure 8-151: Imbruvica Capsule – Price for 28 Capsule & Price Per unit Capsule of 70mg (US$), June’2022
Figure 8-152: Imbruvica Tablet – Price for 28 Tablets & Price Per unit Tablet of Various Doses (US$), June’2022
Figure 8-153: Imbruvica – Recommended Daily Dose by Indication (mg)
Figure 8-154: Imbruvica - Sales Value by Region (US$ Million), Q1’2022
Figure 8-155: Imbruvica – Sales Value by Region (%), Q1’2022
Figure 8-156: Imbruvica –Sales Value (US$ Billion), 2017 - 2021
Figure 8-157: Imbruvica - Sales Value by Region (US$ Million), 2021
Figure 8-158: Imbruvica – Sales Value by Region (%), 2021
Figure 8-159: Global - Imbruvica Quarterly Sales Value (US$ Million), 2021
Figure 8-160: US - Imbruvica Sales Value (US$ Billion), 2017 - 2021
Figure 8-161: US - Imbruvica Quarterly Sales Value (US$ Million), 2021
Figure 8-162: Global – Imbruvica Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-163: US – Imbruvica Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-164: Alimta – US FDA Approval & Orphan Designation
Figure 8-165: Alimta – FDA Approval Year by Dose Regimen
Figure 8-166: Alimta – Patent Issue & Expiration Year
Figure 8-167: Alimta – Price for 100mg & 500mg Intravenous Powder (US$),
June’2022
Figure 8-168: Alimta – Treatment Cycle required in Combination with
Pembrolizumab v/s Cisplatin
Figure 8-169: Alimta – Cost of Single Treatment Cycle & Full Treatment Cost of
NSCLC (US$), June’2022
Figure 8-170: Alimta – US v/s Rest of World Sales Value (US$ Million), Q1’2022
Figure 8-171: Alimta – US v/s Rest of World Sales Value (%), Q1’2022
Figure 8-172: Global - Alimta Sales Value (US$ Billion), 2016 - 2021
Figure 8-173: Alimta – US v/s Rest of World Sales Value (US$ Million), 2021
Figure 8-174: Alimta – US v/s Rest of World Sales Value (%), 2021
Figure 8-175: Alimta – US v/s Rest of World Sales Value (US$ Million), 2020
Figure 8-176: Alimta – US v/s Rest of World Sales Value (%), 2020
Figure 8-177: Global - Alimta Quarterly Sales Value (US$ Million), 2021
Figure 8-178: US - Alimta Quarterly Sales Value (US$ Million), 2021
Figure 8-179: Global - Alimta Quarterly Sales Value (US$ Million), 2020
Figure 8-180: US - Alimta Quarterly Sales Value (US$ Million), 2020
Figure 8-181: Global – Alimta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-182: US – Alimta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-183: Tasigna – FDA Approval Year by Indication
Figure 8-184: Tasigna – Patent Issue & Expiration Year
Figure 8-185: Tasigna – Price for 120 Capsules & Price per unit Capsule of 50mg
(US$), June’2022
Figure 8-186: Tasigna – Price for 28 Capsules & Price per unit Capsule of 150mg &
200mg (US$), June’2022
Figure 8-187: Tasigna – Price for 112 Capsules & Price per unit Capsule of 150mg &
200mg (US$), June’2022
Figure 8-188: Tasigna – Recommended Dose by Indication (mg Twice Daily)
Figure 8-189: Tasigna – Recommended Pediatric Dose by Surface Area (mg Twice
Daily)
Figure 8-190: Global - Tasigna Quarterly Sales Value (US$ Million), Q1’2022 &
Q1’2021
Figure 8-191: Global - Tasigna Sales Value (US$ Million), 2017 - 2021
Figure 8-192: Global - Tasigna Quarterly Sales Value (US$ Million), 2021
Figure 8-193: Global - Tasigna Quarterly Sales Value (US$ Million), 2020
Figure 8-194: Global – Tasigna Sales Forecast (US$ Million), 2022 - 2028
Figure 8-195: Keytruda – Patent Expiration Year by Region
Figure 8-196: Keytruda – US FDA Orphan Designation Year by Indication
Figure 8-197: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous
Injection (US$), June’2022
Figure 8-198: Keytruda – Duration of Single Treatment Cycle & Full Treatment of
Melanoma & Other Cancers (Weeks)
Figure 8-199: Keytruda - Cost of Single & Full Treatment using Solution of Injection
(US$), June’2022
Figure 8-200: Global - Keytruda Sales Value (US$ Million), Q1’2021 & Q1’2022
Figure 8-201: Global - Keytruda Sales Value (US$ Billion), 2018 - 2021
Figure 8-202: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 8-203: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 8-204: Global – Keytruda Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-205: Avastin – Orphan Designation Year by Region
Figure 8-206: Avastin – US FDA Orphan Designation Year by Indication
Figure 8-207: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for
Injection (US$), June’2022
Figure 8-208: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for
Injection (US$), June’2022
Figure 8-209: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for
NSCLC & Metastatic Cervical Cancer (US$), June’2022
Figure 8-210: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for
Recurrent Glioblastoma & Renal Cell Carcinoma (US$), June’2022
Figure 8-211: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal
Cell Carcinoma as Combinational & Monotherapy (Weeks)
Figure 8-212: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for
Recurrent Glioblastoma & Renal Cell Carcinoma (US$), June’2022
Figure 8-213: Avastin – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-214: Avastin – Sales Value by Region (%), Q1’2022
Figure 8-215: Global - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-216: US - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-217: Europe - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-218: Japan - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-219: ROW - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-220: Avastin - Sales Value by Region (US$/CHF Million), 2021
Figure 8-221: Avastin - Sales Value by Region (%), 2021
Figure 8-222: Global - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-223: US - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-224: Global – Avastin Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-225: Tagrisso - Patent Issue & Expiration Year
Figure 8-226: Tagrisso - Price for 30 Tablet Supply & Price per unit of 200 mg Oral
Tablet (US$), June’2022
Figure 8-227: Tagrisso - Recommended & Reduced Dose for NSCLC Treatment (mg
per day)
Figure 8-228: Tagrisso - Sales Value by Region (US$ Million), Q1’2022
Figure 8-229: Tagrisso – Sales Value by Region (%), Q1’2022
Figure 8-230: Tagrisso – Sales Value (US$ Million), 2017 - 2021
Figure 8-231: Tagrisso - Sales Value by Region (US$ Million), 2021
Figure 8-232: Tagrisso – Sales Value by Region (%), 2021
Figure 8-233: Tagrisso - Sales Value by Region (US$ Million), 2020
Figure 8-234: Tagrisso – Sales Value by Region (%), 2020
Figure 8-235: Global - Tagrisso Quarterly Sales Value (US$ Million), 2021
Figure 8-236: Global - Tagrisso Quarterly Sales Value (US$ Million), 2020
Figure 8-237: Global – Tagriso Sales Forecast (US$ Million), 2022 - 2028
Figure 8-238: US – Tagriso Sales Forecast (US$ Million), 2022 - 2028
Figure 8-239: Europe – Tagriso Sales Forecast (US$ Million), 2022 - 2028
Figure 8-240: Herceptin – Approval Year by Cancer Type
Figure 8-241: Herceptin – Orphan Designation Year by Indication
Figure 8-242: Herceptin – Price for a Supply of 10 & Price for Single 150mg Powder
for Injection (US$), June’2022
Figure 8-243: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg)
Figure 8-244: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual
Treatment Cost of Breast Cancer (US$), March’2022
Figure 8-245: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer,
Gastric & Esophageal Carcinoma (mg/kg)
Figure 8-246: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual
Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$),
March’2022
Figure 8-247: Herceptin – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-248: Herceptin – Sales Value by Region (%), Q1’2022
Figure 8-249: Global - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-250: US - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-251: Europe - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-252: Japan - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-253: ROW - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-254: Herceptin - Sales Value by Region (US$/CHF Million), 2021
Figure 8-255: Herceptin - Sales Value by Region (%), 2021
Figure 8-256: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-257: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-258: Global – Hercepin Sales Forecast (US$ Million), 2022 - 2028
Figure 8-259: Darzalex – FDA Approval & Patent Expiration Year
Figure 8-260: Darzalex – FDA Orphan Designation Year by Indication
Figure 8-261: Darzalex – EMA Orphan Designation Year by Indication
Figure 8-262: Darzalex – Price for 5 ml Supply & Price per ml of 20mg/ml
Intravenous Solution (US$), June’2022
Figure 8-263: Darzalex – Price for 20 ml Supply & Price per ml of 20mg/ml
Intravenous Solution (US$), June’2022
Figure 8-264: Darzalex – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 8-265: Darzalex - Sales Value by Region (US$ Million), Q1’2022
Figure 8-266: Darzalex – Sales Value by Region (%), Q1’2022
Figure 8-267: Global - Darzalex Sales Value (US$ Million), 2017 - 2021
Figure 8-268: US - Darzalex Sales Value (US$ Million), 2017 - 2021
Figure 8-269: Darzalex - Sales Value by Region (US$ Million), 2021
Figure 8-270: Darzalex – Sales Value by Region (%), 2021
Figure 8-271: Darzalex – Sales by Region (%), 2019
Figure 8-272: Darzalex – Sales Value by Region (%), 2020
Figure 8-273: Global - Darzalex Quarterly Sales Value (US$ Million), 2021
Figure 8-274: US - Darzalex Quarterly Sales Value (US$ Million), 2021
Figure 8-275: Global - Darzalex Quarterly Sales Value (US$ Million), 2020
Figure 8-276: US - Darzalex Quarterly Sales Value (US$ Million), 2019
Figure 8-277: US - Darzalex Quarterly Sales Value (US$ Million), 2020
Figure 8-278: Global – Darzalex Sales Forecast (US$ Billion), 2022 - 2028
Figure 8-279: US – Darzalex Sales Forecast (US$ Million), 2022 - 2028
Figure 8-280: Venclexta – Approval Year by Region
Figure 8-281: Venclexta – FDA Approval Year by Indication
Figure 8-282: Venclexta – FDA Orphan Designation Year by Indication
Figure 8-283: Venclexta – Orphan Designation Year by Region
Figure 8-284: Venetoclax - Patent Issue & Expiration year
Figure 8-285: Venclexta – Price for 2 Tablet Supply & Price per unit Tablet of 10mg
(US$), June’2022
Figure 8-286: Venclexta – Price for 14 Tablet Supply & Price per unit Tablet of
10mg (US$), June’2022
Figure 8-287: Venclexta – Price for Various Supplies of 50mg Tablet (US$),
June’2022
Figure 8-288: Venclexta – Price for 120 Tablet Supply & Price per unit Tablet of
100mg (US$), June’2022
Figure 8-289: Venclexta – Price for 180 Tablet Supply & Price per unit Tablet of
100mg (US$), June’2022
Figure 8-290: Venclexta – Price for 42 Kit & Price per unit Kit (US$), June’2022
Figure 8-291: Venetoclax Monotherapy – Recommended Dose by Treatment Week
for CLL Management (mg/day)
Figure 8-292: Venetoclax Combinational – Recommended Dose in Initial &
Subsequent Treatment Cycle for CLL (mg/Cycle)
Figure 8-293: Venetoclax Monotherapy – Recommended Dose for AML (mg/day)
Figure 8-294: Venclexta - Sales Value by Region (US$ Million), Q1’2022
Figure 8-295: Venclexta – Sales Value by Region (%), Q1’2022
Figure 8-296: Global - Venclexta Sales Value (US$ Million), 2018 - 2021
Figure 8-297: US - Venclexta Sales Value (US$ Million), 2018 - 2021
Figure 8-298: Venclexta - Sales Value by Region (US$ Million), 2021
Figure 8-299: Venclexta – Sales Value by Region (%), 2021
Figure 8-300: Venclexta - Sales Value by Region (US$ Million), 2020
Figure 8-301: Venclexta – Sales Value by Region (%), 2020
Figure 8-302: Global - Venclexta Quarterly Sales Value (US$ Million), 2021
Figure 8-303: US - Venclexta Quarterly Sales Value (US$ Million), 2021
Figure 8-304: Global - Venclexta Quarterly Sales Value (US$ Million), 2020
Figure 8-305: US - Venclexta Quarterly Sales Value (US$ Million), 2020
Figure 8-306: Global – Venclexta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-307: US – Venclexta Sales Forecast (US$ Million), 2022 - 2028
Figure 8-308: Tecentriq – FDA Approval & Patent Expiration Year
Figure 8-309: Tecentriq – FDA Orphan Designation Year by Indication
Figure 8-310: Tecentriq - Price for 14ml Supply & Price Per ml of 840mg/14ml
Intravenous Injection (US$), June’2022
Figure 8-311: Tecentriq - Price for 20ml Supply & Price Per ml of 1200mg/20ml
Intravenous Injection (US$), June’2022
Figure 8-312: Tecentriq - Average Cost of Single Treatment Cycle & Annual
Treatment using 840mg/2 Week Dose (US$), June’2022
Figure 8-313: Tecentriq - Average Cost of Single Treatment Cycle & Annual
Treatment using 1200mg/3 Week Dose (US$), June’2022
Figure 8-314: Tecentriq - Average Cost of Single Treatment Cycle & Annual
Treatment using 1680mg/4 Week Dose (US$), June’2022
Figure 8-315: Tecentriq – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-316: Tecentriq – Sales Value by Region (%), Q1’2022
Figure 8-317: Global - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-318: US - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-319: Europe - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-320: Japan - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-321: ROW - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-322: Tecentriq - Sales Value by Region (US$/CHF Million), 2021
Figure 8-323: Tecentriq - Sales Value by Region (%), 2021
Figure 8-324: Global - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-325: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-326: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-327: Global – Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-328: US – Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-329: Europe – Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-330: Japan – Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-331: ROW – Tecentriq Sales Forecast (US$ Million), 2022 - 2028
Figure 8-332: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+
Breast Cancer
Figure 8-333: Kadcyla – Patent Expiration Year by Region
Figure 8-334: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous
Powder for Injection (US$), June’2022
Figure 8-335: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of
Early Stage HER2+ Breast Cancer (Weeks)
Figure 8-336: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction
(mg/m2)
Figure 8-337: Global - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-338: US - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-339: Europe - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-340: Japan - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-341: ROW - Kadcyla Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-342: Kadcyla - Sales Value by Region (US$/CHF Million), 2021
Figure 8-343: Kadcyla - Sales Value by Region (%), 2021
Figure 8-344: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-345: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-346: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-347: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-348: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-349: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-350: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-351: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-352: Japan - Kadcyla Quarterly Sales Value (US$/CHF Mill

Report Title: Global Orphan Cancer Drug Market, Drug Sales, Price & Clinical Trials Insight 2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW